Product DescriptionSheep anti-Alpha-synuclein Polyclonal Antibody (Unconjugated), suitable for IHC-Frozen.
Application DetailsIHC with 1:1000 to 1:2000 dilution. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
SpecificityImmunohistochemistry shows a high specificity for alpha-synuclein. This antibody is known to react with human, rat and mouse alpha-synuclein.
Target Host SpeciesHuman
Species ReactivityHuman, Mouse, Rat
Immunogen DescriptionA synthetic peptide (CMPVDPDNEAYEMPSEE) as part of human alpha synuclein (aa: 116-131) conjugated to KLH has been used as the immunogen.
Purity DescriptionWhole serum
Reconstitution InstructionsSpin vial briefly before opening. Reconstitute in 100 µL sterile-filtered, ultrapure water. Centrifuge to remove any insoluble material.
Storage InstructionsAfter reconstitution keep aliquots at -20°C for a higher stability, and at 2-8°C with an appropriate antibacterial agent. Glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles.
Batch NumberPlease see item label.
Expiration Date12 months after date of receipt (unopened vial).
Alternative NamesNon-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
Scientific BackgroundAlpha synuclein is an abundant 140 amino acid neuronal protein, expressed primarily at presynaptic terminals in the central nervous system. Alpha synuclein has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinson's disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated proteinaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as synucleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of alpha-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function.
Specific ReferencesWu W et al. (2022) "Intermediate-length CGG repeat expansion in NOTCH2NLC is associated with pathologically confirmed Alzheimer’s disease"Neurobiol. Aging80(1):447-458; Application: IHC Species: Human
Cong C et al. (2021) "Contribution of Alzheimer's Disease Neuropathologic Change to the Cognitive Dysfunction in Human Brains with Lewy Body-Related Pathology."J Alzheimers Dis.80(1):447-458; Application: IHC Species: Human
Zhang W et al. (2020) "Contribution of Alzheimer's Disease Neuropathologic Change to the Cognitive Dysfunction in Human Brains with Lewy Body-Related Pathology."Neurobiol. Aging[In press]; Application: IHC Species: Human